Stage II Breast Cancer Recruiting Phase 1 Trials for Sargramostim (DB00020)

IndicationStatusPhase
DBCOND0029484 (Stage II Breast Cancer)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02780401Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in RemissionPrevention
NCT03156309Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in RemissionPrevention